According to the American Diabetes Association, approximately 30.3 million Americans, or 9.4% of the population, had diabetes in 2015. Of the 30.3 million adults with diabetes, 23.1 million were diagnosed, and 7.2 million were undiagnosed.
Given the immunomodulatory phenotype of mesenchymal stem cells (MSCs), there is potential (especially in patients with an early diagnosis) that MSCs could help those suffering from Type 2 diabetes.
Transplantation of MSCs in humans for a variety of conditions has been generally well tolerated, although results have been variable as a function of delivery route, and the variability in potency of cells between donors, tissue sources and culture conditions has been well documented.